Quick Answer
ACTUATE THERAPEUTICS, INC. reported Diluted EPS of $1.06 per share (loss) for fiscal year 2025.
ACTUATE THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.06 | +67.5% |
| 2024 | -$3.26 | +81.1% |
| 2023 | -$17.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.25 | +54.5% | +16.7% |
| June 30, 2025 | -$0.30 | +92.9% | +6.3% |
| March 31, 2025 | -$0.32 | +94.1% | +41.8% |
| September 30, 2024 | -$0.55 | +87.2% | +86.9% |
| June 30, 2024 | -$4.20 | -8.2% | +22.2% |
| March 31, 2024 | -$5.40 | — | -25.3% |
| September 30, 2023 | -$4.31 | — | -11.1% |
| June 30, 2023 | -$3.88 | — | — |
- ACTUATE THERAPEUTICS, INC. showed an increase of +67.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, ACTUATE THERAPEUTICS, INC.’s diluted eps has grown by 93.9% (from $17.24 per share (loss) to $1.06 per share (loss)).
- The most recent figure is from ACTUATE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: